________________________________________________________________________________________________________________________________

(C) Wolf G Kroner 2009 - Stefan BorgasSwiss Industrial Biotechnology Network

November 2011. It might be a late start to exploit opportunities of “White Biotechnology”, but it is driven by concerns about weakened competitiveness of the Swiss chemicals industry outside pharma. Moreover, what may appear as one of those familiar biotech success stories is a winding road with many stumbling blocks, Switzerland being no exemption.

Read details from a stakeholder meeting at Basel.

(C) Wolf G Kroner 2009 - Domenico Alexakis

(C) Wolf G Kroner 2009 - Ian Hudson

(C) Wolf G Kroner 2009 - Hans-Peter MeyerRallying stakeholders at a platform meeting in Basel (from left to right, upper row): Stefan Borgas, at the time CEO of Lonzza AG; middle: Domenico Alexakis, Swiss Biotech Association SBA; Ian Hudson, Commercial Director DuPont de Nemours International Sàrl; lower row: Hans-Peter Meyer, at the time responsible for Lonza's biotech projects network initiative.

 

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 3 pages

Full Company License enquire here

Back to section

Editor's Note

Swiss Industrial Biotechnology: Dragged-on networking in the shadow of local big pharma

Former ETH-Professor Armin Fiechter (passed 24/ May 2010) is accredited with introducin technical biochemistry later to become industrial biotechnology in Switzerland. While the country's pharmaceutical industry benefited for many decades from research and inventions no sizable branch of industrial biotechnology developed until the milennium. In middle of the last decade the Swiss Industrial Biocatalysis Consortium was the first serious attempt to build a network of manufacturers (e.g. Lonza, Givaudan), suppliers (e.g. Sigma-Aldrich) and stakeholders like DuPont de Nemours.

The Swiss build-up has been largely in parallel to similar initiatives in Germany (e.g. BASF, Evonik), France (e.g. Arkema, Roquette), Austria (e.g. Agrana, SFB Biokatalyse/TU Graz), in Denmark (Novozymes), or in the United States.

The author of this comment followed it early on as editor of Bioworld Europe (see: Meyer H-P, Münch T (2005): Swiss Industrial Biocatalysis Consortium.
in: Bioworld Europe, issue 1March: 14-16. At the time of the article, Lonza started to roll out a 20 million Swiss Francs programme to interlink relevant academic research, technology developers and key customers in projects requiring biotechnological methods and products (microorganisms, enzymes). Wolf G Kroner

Related Editorial Articles

Make or Break Drug Discovery and Biopharma of Merck Life Science

Bio-based economy? What's in it for business
An industry perspective and key trends in an emerging lead market

Sandro Aruffo's Syngenta Legacy
The late Head of R&D and Robert Berendes, Head of Business Development in a candid conversation about plant biotechnology, cross-fertilization with organic farming, agrichemicals, and prospects in Africa and Asia

Resolving the Innovation Paradox
Günter von Au, Vice-Chairman of Clariant's Board and former CEO Süd-Chemie AG

Merck Serono Manufacturing: We have biosimilars coming …
Includes a comment on changes in Merck’s Swiss operations

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, former Chief Technology Officer Life Sciences at Tecan on strengths and weaknesses of electrowetting development, weaknesses of competitors like Illumina. Prospects of clinical microfluidics

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

Elmar Schnee Leaves Merck KGaA ... and Chemgenex?

Novartis: Adhering to Values Pays Off
Novartis continues to expand the biotech therapeutics pipeline / Focus on emerging markets